JOSEPH LANGSHAW: Open Payments
NPI 1548226129 · CALHOUN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$235,709 in 333 payments from 10 companies in 2025. Trend: 2023 $170,760 · 2024 $239,564 · 2025 $235,709
Speaker / faculty: $162,983Travel & lodging: $67,985Food & beverage: $4,741
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 160 | $155,547 |
| UCB, Inc. | 143 | $68,515 |
| Amgen Inc. | 16 | $11,211 |
| GENZYME CORPORATION | 6 | $251 |
| Galderma Laboratories, L.P. | 2 | $62 |
| Janssen Biotech, Inc. | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Botanix SB Inc | 1 | $21 |
| PFIZER INC. | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $16 |
Products named: RINVOQ, Bimzelx, SKYRIZI, OTEZLA, DUPIXENT, NEMLUVIO, TREMFYA, SOFDRA.
Industry payments across GA — which companies pay providers there.
